Other studies have indeed also confirmed the higher potency of stx2a to cause severe disease (Ethelberg et al., 2004; Buvens and Piérard, 2012; De Rauw et al., 2018b), and a low potency of stx2c similar to that of stx1 to cause HUS (Fuller et al., 2011). Here, STX2 is linked to hemolytic-uremic syndrome.